The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

GEMMA Collins has revealed that she’s dropped two dress sizes after turning to fat loss injections. The TV favourite, 43, who ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.